钙-霍巴喷丁对抗精神病药物所致迟发性运动障碍的临床及生化效应

Clinical and biochemical effects of calcium-hopantenate on neuroleptics-induced tardive dyskinesia.

作者信息

Kashihara K, Ebara T, Yamamoto M, Ogawa T, Harada T, Otsuki S

出版信息

Folia Psychiatr Neurol Jpn. 1985;39(2):147-53. doi: 10.1111/j.1440-1819.1985.tb02898.x.

DOI:10.1111/j.1440-1819.1985.tb02898.x

Abstract

Calcium-hopantenate (HOPA), a derivative of GABA, was administered to 9 psychiatric patients with neuroleptics-induced tardive dyskinesia. In a clinical study, involuntary movements have improved significantly after a 4-8-week medication. Although there was no correlation between the cerebrospinal fluid (CSF) levels of HOPA, GABA, HVA or clinical response, the CSF HOPA levels significantly correlated with changes in the CSF GABA levels. These results suggest that HOPA alleviates the symptoms of tardive dyskinesia being mediated by the central GABAergic mechanisms.

摘要

钙-霍巴喷丁（HOPA），一种γ-氨基丁酸（GABA）的衍生物，被用于治疗9例患有抗精神病药物所致迟发性运动障碍的精神科患者。在一项临床研究中，经过4至8周的药物治疗后，不自主运动有了显著改善。尽管HOPA、GABA、高香草酸（HVA）的脑脊液（CSF）水平与临床反应之间没有相关性，但CSF中HOPA水平与CSF中GABA水平的变化显著相关。这些结果表明，HOPA通过中枢GABA能机制介导来缓解迟发性运动障碍的症状。